{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,25]],"date-time":"2026-03-25T10:53:04Z","timestamp":1774435984310,"version":"3.50.1"},"reference-count":56,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2016,4,30]],"date-time":"2016-04-30T00:00:00Z","timestamp":1461974400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"crossref","award":["81201718"],"award-info":[{"award-number":["81201718"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Molecular Classification, Personalized Diagnosis and Therapy of Nasopharyngeal Carcinoma","award":["2006AA02A404"],"award-info":[{"award-number":["2006AA02A404"]}]},{"name":"National High Technology Research and Development Program of China","award":["2012AA02A501"],"award-info":[{"award-number":["2012AA02A501"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Pharmacokinet"],"published-print":{"date-parts":[[2016,10]]},"DOI":"10.1007\/s40262-016-0395-2","type":"journal-article","created":{"date-parts":[[2016,4,30]],"date-time":"2016-04-30T11:03:19Z","timestamp":1462014199000},"page":"1205-1216","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Pharmacokinetic and Pharmacodynamic Analyses of 5-Fluorouracil in East-Asian Patients with Nasopharyngeal Carcinoma"],"prefix":"10.1007","volume":"55","author":[{"given":"Yuxiang","family":"Ma","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuehao","family":"Lin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Benyan","family":"Zou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wanli","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yang","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Liping","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yan","family":"Huang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yunpeng","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wenfeng","family":"Fang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuanyuan","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jin","family":"Sheng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tao","family":"Qin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhihuang","family":"Hu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Li","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hongyun","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2016,4,30]]},"reference":[{"issue":"9084","key":"395_CR1","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.1016\/S0140-6736(97)07269-3","volume":"350","author":"EE Vokes","year":"1997","unstructured":"Vokes EE, Liebowitz DN, Weichselbaum RR. Nasopharyngeal carcinoma. Lancet. 1997;350(9084):1087\u201391.","journal-title":"Lancet"},{"issue":"8","key":"395_CR2","first-page":"350","volume":"34","author":"LF Zhang","year":"2015","unstructured":"Zhang LF, Li YH, Xie SH, et al. Incidence trend of nasopharyngeal carcinoma from 1987 to 2011 in Sihui County, Guangdong Province, South China: an age-period-cohort analysis. Chin J Cancer. 2015;34(8):350\u20137.","journal-title":"Chin J Cancer."},{"issue":"3","key":"395_CR3","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1186\/s40880-015-0060-4","volume":"34","author":"SM Cao","year":"2015","unstructured":"Cao SM, Xu YJ, Lin GZ, et al. Estimation of cancer burden in Guangdong Province, China in 2009. Chin J Cancer. 2015;34(3):58.","journal-title":"Chin J Cancer."},{"issue":"9476","key":"395_CR4","doi-asserted-by":"crossref","first-page":"2041","DOI":"10.1016\/S0140-6736(05)66698-6","volume":"365","author":"WI Wei","year":"2005","unstructured":"Wei WI, Sham JS. Nasopharyngeal carcinoma. Lancet. 2005;365(9476):2041\u201354.","journal-title":"Lancet"},{"issue":"3","key":"395_CR5","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1007\/s00280-007-0641-2","volume":"62","author":"YH Li","year":"2008","unstructured":"Li YH, Wang FH, Jiang WQ, et al. Phase II study of capecitabine and cisplatin combination as first-line chemotherapy in Chinese patients with metastatic nasopharyngeal carcinoma. Cancer Chemother Pharmacol. 2008;62(3):539\u201344.","journal-title":"Cancer Chemother Pharmacol"},{"issue":"1","key":"395_CR6","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1186\/s40880-015-0076-9","volume":"35","author":"WZ Qiu","year":"2016","unstructured":"Qiu WZ, Huang PY, Shi JL, et al. Neoadjuvant chemotherapy plus intensity-modulated radiotherapy versus concurrent chemoradiotherapy plus adjuvant chemotherapy for the treatment of locoregionally advanced nasopharyngeal carcinoma: a retrospective controlled study. Chin J Cancer. 2016;35(1):2.","journal-title":"Chin J Cancer."},{"key":"395_CR7","first-page":"601","volume":"20","author":"TL Wang","year":"1991","unstructured":"Wang TL, Tan YO. Cisplatin and 5-fluorouracil continuous infusion for metastatic nasopharyngeal carcinoma. Ann Acad Med Singap. 1991;20:601\u20133.","journal-title":"Ann Acad Med Singap"},{"issue":"9","key":"395_CR8","doi-asserted-by":"crossref","first-page":"502","DOI":"10.5732\/cjc.013.10004","volume":"32","author":"HX Lin","year":"2013","unstructured":"Lin HX, Hua YJ, Chen QY, et al. Randomized study of sinusoidal chronomodulated versus flat intermittent induction chemotherapy with cisplatin and 5-fluorouracil followed by traditional radiotherapy for locoregionally advanced nasopharyngeal carcinoma. Chin J Cancer. 2013;32(9):502\u201311.","journal-title":"Chin J Cancer."},{"key":"395_CR9","unstructured":"Scrip\u2019s Cancer Chemotherapy Report. Scrip World Pharmaceutical News. London; 2012."},{"key":"395_CR10","unstructured":"IMS China Market Report. China 5-FU and PTX analystics. Shanghai: IMS Health Inc.; 2012."},{"issue":"1","key":"395_CR11","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/S1040-8428(98)00036-5","volume":"30","author":"E Gamelin","year":"1999","unstructured":"Gamelin E, Boisdron-Celle M. Dose monitoring of 5-fluorouracil in patients with colorectal or head and neck cancer-status of the art. Crit Rev Oncol Hematol. 1999;30(1):71\u20139.","journal-title":"Crit Rev Oncol Hematol"},{"issue":"4","key":"395_CR12","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1200\/JCO.1999.17.4.1105","volume":"17","author":"E Gamelin","year":"1999","unstructured":"Gamelin E, Boisdron-Celle M, Gu\u00e9rin-Meyer V, et al. Correlation between uracil and dihydrouracil plasma ratio, fluorouracil (5-FU) pharmacokinetic parameters, and tolerance in patients with advanced colorectal cancer: a potential interest for predicting 5-FU toxicity and determining optimal 5-FU dosage. J Clin Oncol. 1999;17(4):1105\u201310.","journal-title":"J Clin Oncol"},{"issue":"7","key":"395_CR13","doi-asserted-by":"crossref","first-page":"1171","DOI":"10.1200\/JCO.1992.10.7.1171","volume":"10","author":"G Milano","year":"1992","unstructured":"Milano G, Etienne MC, Cassuto-Viguier E, et al. Influence of sex and age on fluorouracil clearance. J Clin Oncol. 1992;10(7):1171\u20135.","journal-title":"J Clin Oncol"},{"issue":"3","key":"395_CR14","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/j.clcc.2011.03.015","volume":"10","author":"J Saam","year":"2011","unstructured":"Saam J, Critchfield GC, Hamilton SA, et al. Body surface area-based dosing of 5-fluoruracil results in extensive interindividual variability in 5-fluorouracil exposure in colorectal cancer patients on FOLFOX regimens. Clin Colorectal Cancer. 2011;10(3):203\u20136.","journal-title":"Clin Colorectal Cancer."},{"issue":"22","key":"395_CR15","doi-asserted-by":"crossref","first-page":"1543","DOI":"10.1093\/jnci\/djp328","volume":"101","author":"MW Saif","year":"2009","unstructured":"Saif MW, Choma A, Salamone SJ, et al. Pharmacokinetically guided dose adjustment of 5-fluorouracil: a rational approach to improving therapeutic outcomes. J Natl Cancer Inst. 2009;101(22):1543\u201352.","journal-title":"J Natl Cancer Inst"},{"issue":"2","key":"395_CR16","doi-asserted-by":"crossref","first-page":"147","DOI":"10.2165\/00003088-200544020-00002","volume":"44","author":"ME Jonge de","year":"2005","unstructured":"de Jonge ME, Huitema AD, Schellens JH, et al. Individualised cancer chemotherapy: strategies and performance of prospective studies on therapeutic drug monitoring with dose adaptation: a review. Clin Pharmacokinet. 2005;44(2):147\u201373.","journal-title":"Clin Pharmacokinet"},{"issue":"2","key":"395_CR17","first-page":"388","volume":"44","author":"YY Hon","year":"1998","unstructured":"Hon YY, Evans WE. Making TDM work to optimize cancer chemotherapy: a multidisciplinary team approach. Clin Chem. 1998;44(2):388\u2013400.","journal-title":"Clin Chem"},{"issue":"24","key":"395_CR18","doi-asserted-by":"crossref","first-page":"1883","DOI":"10.1093\/jnci\/94.24.1883","volume":"94","author":"SD Baker","year":"2002","unstructured":"Baker SD, Verweij J, Rowinsky EK, et al. Role of body surface area in dosing of investigational anticancer agents in adults, 1991\u20132001. J Natl Cancer Inst. 2002;94(24):1883\u20138.","journal-title":"J Natl Cancer Inst"},{"issue":"13","key":"395_CR19","doi-asserted-by":"crossref","first-page":"2099","DOI":"10.1200\/JCO.2007.13.3934","volume":"26","author":"E Gamelin","year":"2008","unstructured":"Gamelin E, Delva R, Jacob J, et al. Individual fluorouracil dose adjustment based on pharmacokinetic follow-up compared with conventional dosage: results of a multicenter randomized trial of patients with metastatic colorectal cancer. J Clin Oncol. 2008;26(13):2099\u2013105.","journal-title":"J Clin Oncol"},{"issue":"3","key":"395_CR20","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1634\/theoncologist.2011-0357","volume":"17","author":"RR Kaldate","year":"2012","unstructured":"Kaldate RR, Haregewoin A, Grier CE, et al. Modeling the 5-fluorouracil area under the curve versus dose relationship to develop a pharmacokinetic dosing algorithm for colorectal cancer patients receiving FOLFOX6. Oncologist. 2012;17(3):296\u2013302.","journal-title":"Oncologist."},{"issue":"4","key":"395_CR21","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/j.clcc.2012.05.004","volume":"11","author":"O Capitain","year":"2012","unstructured":"Capitain O, Asevoaia A, Boisdron-Celle M, et al. Individual fluorouracil dose adjustment in FOLFOX based on pharmacokinetic follow-up compared with conventional body-area-surface dosing: a phase II, proof-of-concept study. Clin Colorectal Cancer. 2012;11(4):263\u20137.","journal-title":"Clin Colorectal Cancer."},{"issue":"3B","key":"395_CR22","first-page":"2229","volume":"19","author":"M Ychou","year":"1999","unstructured":"Ychou M, Duffour J, Pinguet F, et al. Individual 5FU-dose adaptation schedule using bimonthly pharmacokinetically modulated LV5FU2 regimen: a feasibility study in patients with advanced colorectal cancer. Anticancer Res. 1999;19(3B):2229\u201335.","journal-title":"Anticancer Res"},{"issue":"4","key":"395_CR23","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1007\/s00280-003-0658-0","volume":"52","author":"M Ychou","year":"2003","unstructured":"Ychou M, Duffour J, Kramar A, et al. Individual 5-FU dose adaptation in metastatic colorectal cancer: results of a phase II study using a bimonthly pharmacokinetically intensified LV5FU2 regimen. Cancer Chemother Pharmacol. 2003;52(4):282\u201390.","journal-title":"Cancer Chemother Pharmacol"},{"issue":"6","key":"395_CR24","doi-asserted-by":"crossref","first-page":"1291","DOI":"10.1200\/JCO.1994.12.6.1291","volume":"12","author":"G Milano","year":"1994","unstructured":"Milano G, Etienne MC, Ren\u00e9e N, et al. Relationship between fluorouracil systemic exposure and tumor response and patient survival. J Clin Oncol. 1994;12(6):1291\u20135.","journal-title":"J Clin Oncol"},{"key":"395_CR25","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1186\/1471-2407-12-420","volume":"12","author":"H Ide","year":"2012","unstructured":"Ide H, Kikuchi E, Hasegawa M, et al. Prognostic significance of 5-fluorouracil metabolism-relating enzymes and enhanced chemosensitivity to 5-fluorouracil by 5-chloro 2,4-dihydroxy-pyridine in urothelial carcinoma. BMC Cancer. 2012;12:420.","journal-title":"BMC Cancer"},{"issue":"10","key":"395_CR26","doi-asserted-by":"crossref","first-page":"3223","DOI":"10.1200\/JCO.1997.15.10.3223","volume":"15","author":"CG Leichman","year":"1997","unstructured":"Leichman CG, Lenz HJ, Leichman L, et al. Quantitation of intratumoral thymidylate synthase expression predicts for disseminated colorectal cancer response and resistance to protracted-infusion fluorouracil and weekly leucovorin. J Clin Oncol. 1997;15(10):3223\u20139.","journal-title":"J Clin Oncol"},{"issue":"5","key":"395_CR27","doi-asserted-by":"crossref","first-page":"328","DOI":"10.3816\/CLC.2010.n.041","volume":"11","author":"PP Grimminger","year":"2010","unstructured":"Grimminger PP, Schneider PM, Metzger R, et al. Low thymidylate synthase, thymidine phosphorylase, and dihydropyrimidine dehydrogenase mRNA expression correlate with prolonged survival in resected non-small-cell lung cancer. Clin Lung Cancer. 2010;11(5):328\u201334.","journal-title":"Clin Lung Cancer."},{"issue":"1","key":"395_CR28","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1200\/JCO.1996.14.1.176","volume":"14","author":"HJ Lenz","year":"1996","unstructured":"Lenz HJ, Leichman CG, Leichman L, et al. Thymidylate synthase mRNA level in adenocarcinoma of the stomach: a predictor for primary tumor response and overall survival. J Clin Oncol. 1996;14(1):176\u201382.","journal-title":"J Clin Oncol"},{"issue":"5","key":"395_CR29","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1093\/annonc\/mdm599","volume":"19","author":"R Soong","year":"2008","unstructured":"Soong R, Shah N, Iacopetta B, et al. Prognostic significance of thymidylate synthase, dihydropyrimidine dehydrogenase and thymidine phosphorylase protein expression in colorectal cancer patients treated with or without 5-fluorouracil-based chemotherapy. Ann Oncol. 2008;19(5):915\u20139.","journal-title":"Ann Oncol."},{"issue":"3","key":"395_CR30","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1200\/JCO.2004.05.064","volume":"22","author":"S Popat","year":"2004","unstructured":"Popat S, Matakidou A, Houlston RS. Thymidylate synthase expression and prognosis in colorectal cancer: a systematic review and meta-analysis. J Clin Oncol. 2004;22(3):529\u201336.","journal-title":"J Clin Oncol"},{"issue":"10","key":"395_CR31","doi-asserted-by":"crossref","first-page":"1304","DOI":"10.1097\/01.pas.0000170346.55304.88","volume":"29","author":"C Jakob","year":"2005","unstructured":"Jakob C, Liersch T, Meyer W, et al. Immunohistochemical analysis of thymidylate synthase, thymidine phosphorylase, and dihydropyrimidine dehydrogenase in rectal cancer (cUICC II\/III): correlation with histopathologic tumor regression after 5-fluorouracil-based long-term neoadjuvant chemoradiotherapy. Am J Surg Pathol. 2005;29(10):1304\u20139.","journal-title":"Am J Surg Pathol"},{"issue":"12","key":"395_CR32","first-page":"4097","volume":"5","author":"H Shiga","year":"1999","unstructured":"Shiga H, Heath EI, Rasmussen AA, et al. Prognostic value of p53, glutathione S-transferase pi, and thymidylate synthase for neoadjuvant cisplatin-based chemotherapy in head and neck cancer. Clin Cancer Res. 1999;5(12):4097\u2013104.","journal-title":"Clin Cancer Res"},{"key":"395_CR33","first-page":"27","volume":"2","author":"K Aubry","year":"2008","unstructured":"Aubry K, Labourey JL, Bess\u00e8de JP, et al. Expression levels of thymidylate synthase, thymidylate phosphorylase and dihydropyrimidine dehydrogenase in head and neck squamous cell carcinoma: preliminary study. Clin Med Oncol. 2008;2:27\u201335.","journal-title":"Clin Med Oncol."},{"issue":"4","key":"395_CR34","first-page":"1235","volume":"9","author":"JR Bertino","year":"2003","unstructured":"Bertino JR, Banerjee D. Is the measurement of thymidylate synthase to determine suitability for treatment with 5-fluoropyrimidines ready for prime time. Clin Cancer Res. 2003;9(4):1235\u20139.","journal-title":"Clin Cancer Res"},{"key":"395_CR35","first-page":"111","volume":"28","author":"HL McLeod","year":"1999","unstructured":"McLeod HL, Milne LH, Johnston SJ. 5-Fluorouracil metabolizing enzymes. Methods Mol Med. 1999;28:111\u201320.","journal-title":"Methods Mol Med"},{"issue":"23","key":"395_CR36","doi-asserted-by":"crossref","first-page":"4298","DOI":"10.1200\/JCO.2001.19.23.4298","volume":"19","author":"Y Shirota","year":"2001","unstructured":"Shirota Y, Stoehlmacher J, Brabender J, et al. ERCC1 and thymidylate synthase mRNA levels predict survival for colorectal cancer patients receiving combination oxaliplatin and fluorouracil chemotherapy. J Clin Oncol. 2001;19(23):4298\u2013304.","journal-title":"J Clin Oncol"},{"issue":"2","key":"395_CR37","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1002\/jso.10137","volume":"81","author":"T Nakagawa","year":"2002","unstructured":"Nakagawa T, Tanaka F, Takata T, et al. Predictive value of dihydropyrimidine dehydrogenase expression in tumor tissue, regarding the efficacy of postoperatively administered UFT (Tegafur\u00a0+\u00a0Uracil) in patients with p-stage I nonsmall-cell lung cancer. J Surg Oncol. 2002;81(2):87\u201392.","journal-title":"J Surg Oncol"},{"key":"395_CR38","doi-asserted-by":"crossref","first-page":"811","DOI":"10.2147\/OTT.S46498","volume":"6","author":"H Zhao","year":"2013","unstructured":"Zhao H, Zhao Y, Guo Y, et al. Clinical significance of the thymidylate synthase, dihydropyrimidine dehydrogenase, and thymidine phosphorylase mRNA expressions in hepatocellular carcinoma patients receiving 5-fluorouracil-based transarterial chemoembolization treatment. Onco Targets Ther. 2013;6:811\u20138.","journal-title":"Onco Targets Ther."},{"key":"395_CR39","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.2147\/OTT.S65067","volume":"7","author":"HY Zhao","year":"2014","unstructured":"Zhao HY, Ma GW, Zou BY, et al. Prognostic significance of thymidylate synthase in postoperative non-small cell lung cancer patients. Onco Targets Ther. 2014;7:1301\u201310.","journal-title":"Onco Targets Ther."},{"issue":"5","key":"395_CR40","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1097\/00007691-199810000-00013","volume":"20","author":"AJ Wood","year":"1998","unstructured":"Wood AJ. Ethnic differences in drug disposition and response. Ther Drug Monit. 1998;20(5):525\u20136.","journal-title":"Ther Drug Monit"},{"issue":"5","key":"395_CR41","doi-asserted-by":"crossref","first-page":"373","DOI":"10.2165\/00003088-198207050-00001","volume":"7","author":"W Kalow","year":"1982","unstructured":"Kalow W. Ethnic differences in drug metabolism. Clin Pharmacokinet. 1982;7(5):373\u2013400.","journal-title":"Clin Pharmacokinet"},{"issue":"6","key":"395_CR42","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1038\/nrc1629","volume":"5","author":"SD Undevia","year":"2005","unstructured":"Undevia SD, Gomez-Abuin G, Ratain MJ. Pharmacokinetic variability of anticancer agents. Nat Rev Cancer. 2005;5(6):447\u201358.","journal-title":"Nat Rev Cancer"},{"issue":"1","key":"395_CR43","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/j.ijrobp.2007.02.032","volume":"69","author":"AD King","year":"2007","unstructured":"King AD, Zee B, Yuen EH, et al. Nasopharyngeal cancers: which method should be used to measure these irregularly shaped tumors on cross-sectional imaging? Int J Radiat Oncol Biol Phys. 2007;69(1):148\u201354.","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"6","key":"395_CR44","doi-asserted-by":"crossref","first-page":"1683","DOI":"10.1200\/JCO.20.6.1683","volume":"20","author":"AA Adjei","year":"2002","unstructured":"Adjei AA, Reid JM, Diasio RB, et al. Comparative pharmacokinetic study of continuous venous infusion fluorouracil and oral fluorouracil with eniluracil in patients with advanced solid tumors. J Clin Oncol. 2002;20(6):1683\u201391.","journal-title":"J Clin Oncol"},{"issue":"6","key":"395_CR45","first-page":"694","volume":"18","author":"YH Li","year":"1999","unstructured":"Li YH, Xu RH, Liao H, et al. A pilot study of 5-FU circadian pharmacokinetics in patients with nasopharyngeal carcinoma. Chin J Cancer. 1999;18(6):694\u2013703.","journal-title":"Chin J Cancer."},{"issue":"2","key":"395_CR46","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1002\/rcm.3362","volume":"22","author":"JE Kosovec","year":"2008","unstructured":"Kosovec JE, Egorin MJ, Gjurich S, et al. Quantitation of 5-fluorouracil (5-FU) in human plasma by liquid chromatography\/electrospray ionization tandem mass spectrometry. Rapid Commun Mass Spectrom. 2008;22(2):224\u201330.","journal-title":"Rapid Commun Mass Spectrom"},{"issue":"6","key":"395_CR47","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1097\/FTD.0b013e3181b9b8c0","volume":"31","author":"JH Beumer","year":"2009","unstructured":"Beumer JH, Boisdron-Celle M, Clarke W, et al. Multicenter evaluation of a novel nanoparticle immunoassay for 5-fluorouracil on the Olympus AU400 analyzer. Ther Drug Monit. 2009;31(6):688\u201394.","journal-title":"Ther Drug Monit"},{"issue":"8 Suppl","key":"395_CR48","first-page":"4244s","volume":"46","author":"KS McCarty Jr","year":"1986","unstructured":"McCarty KS Jr, Szabo E, Flowers JL, et al. Use of a monoclonal anti-estrogen receptor antibody in the immunohistochemical evaluation of human tumors. Cancer Res. 1986;46(8 Suppl):4244s\u20138s.","journal-title":"Cancer Res"},{"issue":"11 Pt 2","key":"395_CR49","doi-asserted-by":"crossref","first-page":"2419","DOI":"10.1093\/clinchem\/39.11.2419","volume":"39","author":"AJ Galpin","year":"1993","unstructured":"Galpin AJ, Evans WE. Therapeutic drug monitoring in cancer management. Clin Chem. 1993;39(11 Pt 2):2419\u201330.","journal-title":"Clin Chem."},{"issue":"3","key":"395_CR50","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1093\/jjco\/28.3.168","volume":"28","author":"K Ikeda","year":"1998","unstructured":"Ikeda K, Terashima M, Kawamura H, et al. Pharmacokinetics of cisplatin in combined cisplatin and 5-fluorouracil therapy: a comparative study of three different schedules of cisplatin administration. Jpn J Clin Oncol. 1998;28(3):168\u201375.","journal-title":"Jpn J Clin Oncol"},{"issue":"6","key":"395_CR51","first-page":"1676","volume":"48","author":"E Petit","year":"1988","unstructured":"Petit E, Milano G, L\u00e9vi F, et al. Circadian rhythm-varying plasma concentration of 5-fluorouracil during a five-day continuous venous infusion at a constant rate in cancer patients. Cancer Res. 1988;48(6):1676\u20139.","journal-title":"Cancer Res"},{"key":"395_CR52","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1093\/jnci\/85.2.95","volume":"85","author":"IW Dimery","year":"1993","unstructured":"Dimery IW, Hong WK. Overview of combined modality therapies for head and neck cancer. J Natl Cancer Inst. 1993;85:95\u2013111.","journal-title":"J Natl Cancer Inst"},{"issue":"2","key":"395_CR53","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/j.canlet.2008.09.010","volume":"274","author":"Y Tateishi","year":"2009","unstructured":"Tateishi Y, Tatemoto Y, Ohno S, et al. Combined evaluation of dihydropyrimidine dehydrogenase and thymidine phosphorylate mRNA levels in tumor predicts the histopathological effect of 5-fluorouracil-based chemoradiotherapy. Cancer Lett. 2009;274(2):187\u201393.","journal-title":"Cancer Lett"},{"issue":"3","key":"395_CR54","first-page":"203","volume":"40","author":"ZQ Tao","year":"2005","unstructured":"Tao ZQ, Liu SC, Si YF, et al. Relationship between expression of multidrug-resistant genes in nasopharyngeal carcinoma tissue and sensitivity to chemotherapy. Zhonghua Er Bi Yan Hou Tou Jing Wai Ke Za Zhi. 2005;40(3):203\u20137.","journal-title":"Zhonghua Er Bi Yan Hou Tou Jing Wai Ke Za Zhi."},{"issue":"3","key":"395_CR55","first-page":"238","volume":"16","author":"YS Zong","year":"2000","unstructured":"Zong YS, Wu QL, Liang XM, et al. Histological typing of primary nasopharyngeal carcinomas-a sum-up of experience from past 30 years. J Clin Exp Pathol. 2000;16(3):238\u201343.","journal-title":"J Clin Exp Pathol."},{"issue":"1","key":"395_CR56","first-page":"197","volume":"50","author":"BE Harris","year":"1990","unstructured":"Harris BE, Harris BE, Song R, Soong SJ, et al. Relationship between dihydropyrimidine dehydrogenase activity and plasma 5-fluorouracil levels with evidence for circadian variation of enzyme activity and plasma drug levels in cancer patients receiving 5-fluorouracil by protracted continuous infusion. Cancer Res. 1990;50(1):197\u2013201.","journal-title":"Cancer Res"}],"updated-by":[{"DOI":"10.1007\/s40262-017-0615-4","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2017,12,26]],"date-time":"2017-12-26T00:00:00Z","timestamp":1514246400000}}],"container-title":["Clinical Pharmacokinetics"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40262-016-0395-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40262-016-0395-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40262-016-0395-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40262-016-0395-2","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,9,19]],"date-time":"2020-09-19T08:28:09Z","timestamp":1600504089000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40262-016-0395-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,4,30]]},"references-count":56,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2016,10]]}},"alternative-id":["395"],"URL":"https:\/\/doi.org\/10.1007\/s40262-016-0395-2","relation":{"correction":[{"id-type":"doi","id":"10.1007\/s40262-017-0615-4","asserted-by":"object"}]},"ISSN":["0312-5963","1179-1926"],"issn-type":[{"value":"0312-5963","type":"print"},{"value":"1179-1926","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,4,30]]}}}